p-Dimethylaminoazobenzene. 4-Dimethylaminoazobenzene . Methyl Yellow . p-Dimethylaminoazobenzene, (E)-Isomer . p-Dimethylaminoazobenzene, (Z)-Isomer . 4 Dimethylaminoazobenzene . p Dimethylaminoazobenzene . Butter Yellow . Dimethylaminoazobenzene . DAB 18460 . A reagent used mainly to induce experimental liver cancer. According to the Fourth Annual Report on Carcinogens (NTP 85-002, p. 89) published in 1985, this compound "may reasonably be anticipated to be a carcinogen." (Merck, 11th ed) . 1.00
Egtazic Acid. EGATA . Egtazic Acid Disodium Salt . Egtazic Acid Potassium Salt . Egtazic Acid Sodium Salt . Ethylene Glycol Bis(2-aminoethyl ether)tetraacetic Acid . Ethylenebis(oxyethylenenitrile)tetraacetic Acid . GEDTA . Glycoletherdiamine-N,N,N',N'-tetraacetic Acid . Magnesium-EGTA . Tetrasodium EGTA . Acid, Egtazic . EGTA, Tetrasodium . Magnesium EGTA . Ethylene Glycol Tetraacetic Acid . EGTA 18466 . A chelating agent relatively more specific for calcium and less toxic than EDETIC ACID. . 0.45
Diagnosis-Related Groups. Case Mixes . DRGs 18471 . Diagnostic-Related Group . Group, Diagnostic-Related . Groups, Diagnostic-Related . Diagnosis Related Groups . Diagnosis-Related Group . Diagnostic Related Group . Diagnostic-Related Groups . Group, Diagnosis-Related . Group, Diagnostic Related . Groups, Diagnosis-Related . Groups, Diagnostic Related . Case Mix . DRG 18471 . A system for classifying patient care by relating common characteristics such as diagnosis, treatment, and age to an expected consumption of hospital resources and length of stay. Its purpose is to provide a framework for specifying case mix and to reduce hospital costs and reimbursements and it forms the cornerstone of the prospective payment system. . 0.45
Dabigatran. BIBR 1048 . Dabigatran Etexilate . Dabigatran Etexilate Mesylate . N-((2-(((4-(aminoiminomethyl)phenyl)amino)methyl)-1-methyl-1H-benzimidazol-5-yl)carbonyl)-N-2-pyridinyl-beta-alanine . Pradaxa . Etexilate Mesylate, Dabigatran . Etexilate, Dabigatran . Mesylate, Dabigatran Etexilate . A THROMBIN inhibitor which acts by binding and blocking thrombogenic activity and the prevention of thrombus formation. It is used to reduce the risk of stroke and systemic EMBOLISM in patients with nonvalvular atrial fibrillation. . 0.44